Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Farmers Insurance
Cantor Fitzgerald
Express Scripts
Julphar
Baxter

Generated: September 23, 2019

DrugPatentWatch Database Preview

Patent: 9,814,780

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,814,780
Title:Compositions for inducing antigen-specific tolerance
Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.
Inventor(s): Hubbell; Jeffrey A. (Lausanne, CH), Kontos; Stephan (Lausanne, CH), Dane; Karen Y. (Lausanne, CH)
Assignee: ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (Lausanne, CH)
Application Number:15/232,694
Patent Claims:see list of patent claims

Details for Patent 9,814,780

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck ELSPAR asparaginase VIAL 101063 001 1978-01-10 ➤ Sign Up ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (Lausanne, CH) 2031-08-09 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
QuintilesIMS
US Department of Justice
Chinese Patent Office
Teva
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.